GUJARAT INJECT (KERALA) LIMITED

CIN: L18100KL1991PLC005926

Regd Office: Bldg No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad – 678 621

Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara – 390 005

Phones: 09898593314, 09712193314

E-Mail: gikl2015@hotmail.com Website: www.gujaratinject.in

Date: February 13, 2024

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001.

Dear Sir,

Sub: Outcome of Board meeting held today i.e. on February 13, 2024 and Standalone Unaudited Financial

Results for the quarter and nine months ended December 31, 2023

Ref: Gujarat Inject (Kerala) Limited (Security Id/Code: GUJINJEC / 524238)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on February 13, 2024, at the Administrative Office of the Company which was commenced at 04:30 P.M. and concluded at 05:00 P.M. have transacted following businesses:

- 1) Considered, approved and took on record the Unaudited Financial Results for the quarter and nine months ended on December 31, 2023 along with the limited review report. In this regards, we are submitting the followings:
 - a) Unaudited Financial Results for the quarter and nine months ended on December 31, 2023;
 - b) Limited Review Report;

There is no other business to be transacted apart from this.

Kindly take the same on your record and oblige us.

Thanking you

For, Gujarat Inject Kerala Limited

Murli Shivshankaran Nair Wholetime Director

DIN: 02243039

Place: Vadodara

GUJARAT INJECT KERALA LIMITED

CIN : L18100KL1991PLC005926 Registered Office: Building No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad - 678 621 Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, SayaJiganj, Vadodara - 390005

Statement of Financial Results for the Quarter ended on December 31. 2023

(₹ In Lakh except per share data) Quarter Ended 9 MONTH ENDED Year Ended Particulars 30-09-2023 31-12-2023 31-12-2022 31-03-2023 31-12-2023 31-12-2022 Date of start of reporting period Date of end of reporting period 01-04-2022 31-12-2022 01-10-2023 01-07-2023 01-10-2022 01-04-2023 01-04-2022 31-12-2022 В 30-09-2023 31-03-2023 31-12-202 Audited Audited Whether results are audited or unaudited Unaudited Unaudited Unaudited Unaudited D Nature of report standalone or consolidated Standalone Standalone Standalone Standalone Standalone Standalone Revenue From Operations Net sales or Revenue from Operations 21.59 10.04 36.96 17.38 17.38 43.25 Other Income 6.06 10.04 Total Income (l+Il) 25.33 2.32 43.02 57.62 60.63 IV Expenses Cost of materials consumed 6.18 (a) Purchases of stock-in-trade Changes in inventories of finished goods, work-in-progress 15.34 9.20 26.23 9.20 14.50 0.89 (c) and stock-in-trade (d) 1.08 2.79 0.36 0.36 Employee benefit expense 0.46 1.18 Finance Costs 0.00 0.00 (f) Depreciation and amortisation expense 8.92 0.30 36.43 36.91 0.15 9.63 Other Expenses (g) Manufacturing Expenses (i) Sales & Promotion Expenses Administrative Expenses (j) 24.72 Total expenses (IV)
Profit/(loss) before exceptional items and tax (III-IV) 0.66 9.71 37.04 52.89 55.09 0.33 5.98 0.61 1.66 4.73 5.54 Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) 0.61 1.66 5.98 4.73 5.54 0.33 VIII Tax Expense 0.41 0.09 1.23 0.15 1.50 1.44 1.23 1.44 0.41 0.09 Current Tax (b) (Less):- MAT Credit Current Tax Expense Relating to Prior years (c) Deferred Tax (Asset)/Liabilities (d) Profit (Loss) for the period from continulng operations IX 0.46 1.25 0.24 4.48 3.50 4.10 (VII-VIII) Profit/(loss) from discontinued operations Tax expenses of discontinued operations
Profit/(loss) from Discontinued operations (after tax) (X-ΧI XII 0.46 1.25 0.24 4.48 3.50 4.10 XIII A Profit(Loss) For Period Before Minority Interest
XIII R Share Of Profit / Loss of Associates and joint ventures XIII B accounted for using equity method XIII C Profit/Loss Of Minority Interset XIV Profit (Loss) for the period (XIII A + XIII B + XIII C) 0.46 1.25 0.24 4.48 3.50 4.10 Other Comprehensive Income a. i). Items that will not be reclassifled to proflt or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassifed to profit or loss ii). Income tax relating to items that will be reclassifed to profit or loss Total Comprehensive income Total Comprehensive income [Comprising Profit for the 0.46 1.25 0.24 4.48 3.50 4.10 Period and Other comprehensive income] (XIV+XV) Details of equity share capital 488.48 10.00 Paid-up equity share capital 488.48 488.48 488.48 488.48 488.48 Face value of equity share capital (Per Share) 10.00 10.00 10.00 10.00 10.00 Earnings per share Earnings per share (not annualised for quarter ended) 0.03 0.09 0.07 Basic earnings (loss) per share from continuing operation 0.01 0.00 0.08 Diluted earnings (loss) per share from continuing operation 0.01 0.03 0.00 0.09 0.07 0.08 Earnings per share (not annualised for quarter ended) Basic earnings (loss) per share from discontinued operation Diluted earnings (loss) per share from discontinued operation Earnings per share (not annualised for quarter ended) Basic earnings (loss) per share from continuing and 0.07 0.01 0.03 0.00 0.09 0.08 discotinued operations Diluted earnings (loss) per share continuing and 0.07 0.01 0.03 0.00 0.09 0.08

discotinued operations





GUJARAT INJECT KERALA LIMITED

CIN: L18100KL1991PLC005926

Registered Office: Building No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad - 678 621
Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, SayaJiganj, Vadodara - 390005

Notes on Financial Results:-	
1	The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
	The above Unaudited financial results for the quarter ended December 31, 2023 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on February 13, 2024. The statutory auditors have carried out limited review of above result.
	The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
4	As per Indian Accounting Standard 108 on "Operating Segment" (Ind AS 108), the Company has only one reportable segment. i.e. Trading



For Gujarat Inject Kerala Limited

Murli Nair Whole Time Director DIN 02243039

Date :- 13-Feb-24 Place:- Vadodara



S. MANDAWAT & CO.

Chartered Accountants

913, Sahjanand Shopping Centre Opp. Rajasthan Hindi High School Shahibaug Road-Ahmedabad - 380004 Phone: (O) 25620913 (M) 9426072909 Email: skmandawat@yahoo.co.in

LIMITED REVIEW REPORT ON QUARTERLY STANDALONE FINANCIAL RESULTS OF GUJARAT INJECT KERALA LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LODR) REGULATIONS, 2015 AS AMENDED, READ WITH SEBI CIRCULAR NO. CIR/CFD/CMD1/44/2019

To,

The Board of Directors of Gujarat Inject Kerala Limited,

SB-06, Paradise Complex, Opp. M.S. University, Sayajigani, Vadodara – 390 005

We have reviewed the accompanying statement of standalone unaudited financial results of Gujarat Inject Kerala Limited for the Quarter ended December 31, 2023. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 (the Listing Regulation, 2015), as amended. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed interims of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. S. Mandawat& Co. Chartered Accountants

Firm's Registration No: 118330W

CA Subhash Chandra Mandawat

Partner

Membership No. 102708

Place: Ahmedabad Date: 13/02/2024

Udin:- 24102708BKENLR9435